UNSPSC 51144115: Dextroamphetamine

This classification denotes a cns stimulant with the molecular formula C9H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ47U051FI, chemically known as phenethylamine, alpha-methyl-, d- but more generally known as dexamfetamine, which bears US NIH Compound Identifier 5826. European Medicines Agency schedules Dexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07019MIG. The term DEXAMFETAMINE is an International Non-Proprietary Name.

UNSPSC 51144115 Dextroamphetamine is a Commodity code covering controlled pharmaceutical substances procured by state and local health and human services agencies for treatment, overdose response, and public health programs. Recent state and local solicitations under this code reflect procurement of controlled-substance medications and pharmaceutical supply systems through formal bidding processes, cooperative purchasing agreements, and exploratory market-research mechanisms designed to establish direct relationships with manufacturers and wholesalers. State and local issuing bodies acquiring under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, solicited naloxone and drug deactivation systems through an IFB mechanism, while the Texas Health and Human Services Commission issued a market-research RFI to evaluate direct-to-manufacturer prescription fulfillment capabilities. Vendors bidding on these opportunities must comply with controlled-substance handling requirements, DEA registration and licensing, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA requirements, E-Verify employment verification, drug-free workplace certification, and comprehensive insurance coverage including commercial general liability and professional liability. Contracts typically include probationary periods, performance penalties for compliance failures, and audit and record-inspection rights.

Procurement activity under this code spans multiple states, with recent solicitations in Florida, Texas, Minnesota, and Oregon. Seminole County's IFB for naloxone and safe drug deactivation systems (due July 26, 2023) sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries and fixed-fee pricing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) requiring vendors to supply through three authorized wholesalers with contract terms of two years and optional extensions, pricing weighted at 75 percent of evaluation criteria, and a 3 percent administrative fee on all purchases. The Texas Health and Human Services Commission's RFI (due April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, indicating early-stage state interest in alternative supply models for prescription fulfillment.